Adrenocortical carcinoma (ACC) generally has poor prognosis. Existing treatments provide limited benefit for most patients with locally advanced or metastatic tumors. We investigated the mechanisms for the cytotoxicity, xenograft suppression, and adrenalytic activity of ATR-101 (PD132301-02), a prospective agent for ACC treatment. Oral administration of ATR-101 inhibited the establishment and impeded the growth of ACC-derived H295R cell xenografts in mice. ATR-101 induced H295R cell apoptosis in culture and in xenografts. ATR-101 caused mitochondrial hyperpolarization, reactive oxygen release, and ATP depletion within hours after exposure, followed by cytochrome c release, caspase-3/7 activation, and membrane permeabilization. The increase in mitochondrial membrane potential occurred concurrently with the decrease in cellular ATP levels. When combined with ATR-101, lipophilic free radical scavengers suppressed the reactive oxygen release, and glycolytic precursors prevented the ATP depletion, abrogating ATR-101 cytotoxicity. ATR-101 directly inhibited F1F0-ATPase activity and suppressed ATP synthesis in mitochondrial fractions. ATR-101 administration to guinea pigs caused oxidized lipofuscin accumulation in the zona fasciculata layer of the adrenal cortex, implicating reactive oxygen release in the adrenalytic effect of ATR-101. These results support the development of ATR-101 and other adrenalytic compounds for the treatment of ACC.
Introduction
A classical approach for the development of anti-cancer drugs is based on the identification of compounds that have selective toxicity in specific normal cells or tissues (Goodman et al. 1946 , Bergenstal et al. 1959 . In order to develop such compounds for therapeutic use, it is essential to determine their efficacy in cell and animal models of cancer and to characterize their molecular mechanisms of action.
Adrenocortical carcinoma (ACC) is an aggressive disease with poor prognosis and few treatment options (Else et al. 
Figure 1
Inhibition of ACC cell xenograft establishment and growth by ATR-101, (A) Xenograft growth in mice that were administered ATR-101 (1 mg/g/day p.o.) or vehicle starting when the mean size of the xenografts reached 100 mm 3 . The median and middle quartiles of the xenograft sizes and weights are plotted for each cohort. The median body weight for each cohort is shown in the graph on the right. (B) Xenograft establishment and growth, and urinary free cortisol levels in mice that were administered ATR-101 (0.7 mg/kg/day p.o.) or vehicle starting 2 weeks after cell implantation. The sizes of the xenografts in individual mice that were administered vehicle (upper graph) or ATR-101 (middle graph) are plotted as a function of the time after beginning the administration. The levels of urinary free cortisol were measured in the mice from each cohort, and the mean and standard deviation are plotted as a function of the time after beginning the administration (bottom graph). (C) Pharmacokinetic analysis of the minimum serum concentration of ATR-101 that affected xenograft growth in mice. The concentration of ATR-101 in serum was measured using LC-MS at the times indicated after the administration of a single dose (0.3 mg/g p.o.) of ATR-101. Each symbol indicates serum samples that were collected from the same mouse. (D) Effects of long-term ATR-101 administration to mice on the sensitivity of cells re-isolated from the xenografts to ATR-101. The ATP levels of H295R cells and cells that were re-isolated from the xenografts of mice that had been administered ATR-101 for 110 days were compared after 16 h of culture in the presence of the indicated concentrations of ATR-101 or vehicle. The graph shows the means and standard deviations of three parallel cultures and is representative of two independent experiments. (E) Effects of ATR-101 administration on the proportions of cortical xenograft cells that were stained by anti-BrdU antibodies (upper left graph), anti-Ki67 antibodies (upper right graph), and TUNEL reagents (lower left graph and lower right images). The median, middle quartiles, and range are plotted for each cohort. The results shown are representative of two or more independent experiments. (*P < 0.05, Mann-Whitney non-parametric U-test, n = 6). A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-15-0527.
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produces a tumor response in one-quarter to one-third of ACC patients with locally advanced disease (Fassnacht et al. 2012) . We sought to identify a new agent for ACC treatment and to characterize its mechanisms of action in cultured cells and animals.
To identify agents that could be used for ACC treatment, we focused on compounds that cause selective damage to the adrenal cortex (adrenalytic activity). Some inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT; sterol O-acyl transferase; SOAT), which were originally developed for the treatment of atherosclerosis, have adrenalytic activity (Sliskovic & White 1991) . In particular, ATR-101 has adrenalytic activity in guinea pigs, beagle dogs, and cynomolgus monkeys (Dominick et al. 1993a ,b, Reindel et al. 1994 . ATR-101 reduces the ATP level in the adrenal cortex of guinea pigs and in cultured adrenocortical cells (Vernetti et al. 1993 , Wolfgang et al. 1995 . ATR-101 cytotoxicity correlates with the inhibition of respiration in primary adrenocortical cells and in mitochondrial fractions (Vernetti et al. 1993) . The observed toxicity of ATR-101 is limited to the adrenal cortex and to the ovaries and sebaceous glands in cynomolgus monkeys (Reindel et al. 1994) . The selective adrenalytic activity of ATR-101 suggests that it could be used to treat diseases that are caused by excess adrenocortical cell growth or activity.
A subset of other ACAT inhibitors can affect adrenocortical functions (Sliskovic et al. 1998 , Nishimura et al. 2013 . However, many potent ACAT inhibitors, such as avasimibe (CI-1011), eflucimibe (F 12511), and pactimibe sulfate (CS-505), do not have detectable adrenalytic activity (Junquero et al. 2001 , Robertson et al. 2001 , Kotsuma et al. 2008 . Targeted deletion of the mouse gene that encodes the adrenocortical ACAT1 enzyme (Acact) depletes cholesterol esters in adrenals; however, it does not cause corticosteroid insufficiency (Meiner et al. 1996) . It is therefore likely that the adrenalytic activity of ATR-101 involves molecular mechanisms unrelated to ACAT inhibition.
To evaluate the efficacy and mechanisms of ATR-101 action in cell and animal models of ACC, we investigated the effects of ATR-101 on ACC-derived cells in culture and mouse xenografts. We compared the mechanisms of ATR-101 in vitro with its adrenalytic activity in vivo.
Materials and methods

Cell culture and pharmacological reagents
NCI H295R cells were obtained from American Type Culture Collection (ATCC) and were maintained in DMEM:F-12 medium with 10% FCS at 37˚C in an atmosphere of 5% CO 2 . The cells were validated by determining the transcription of genes and synthesis of corticosteroids that are characteristic for the NCI 295R cell line. The NCI H295R cell line is the most extensively characterized ACC-derived cell line and carries a mutation in the CTNNB1 gene, which is the most frequently observed mutation in ACC tumors (Assie et al. 2014 , Juhlin et al. 2015 , Pinto et al. 2015 . To investigate the effects of ATR-101, the cells were transferred into DMEM with 5% FCS, 10 mM galactose, 2 mM glutamine and 1 mM sodium pyruvate at least 24 h before each experiment.
ATR-101 was synthesized by AAPharmasyn (Ann Arbor, MI, USA) and by PharmAgra Labs (Brevard, NC, USA) and was purified to 97% homogeneity using protocols similar to those that have been described in Trivedi et al. (1994) .
Experimental animals, analysis of ATR-101 effects on xenografts, and adrenalytic activity CB17-SCID mice with H295R cell xenografts were produced and the effects of ATR-101 administration were analyzed using protocols adapted from previous studies (Barlaskar et al. 2009 ). To measure the effects of ATR-101 on xenograft growth, the mice were randomized into groups that had similar distributions of xenograft sizes with an average of 100 mm 3 . To measure the effects of ATR-101 on xenograft establishment, the sizes of swelling produced by cell implantation were measured twice during the week after cell injection, and the mice were randomized into groups that had similar distributions of the sizes of the swellings. Urinary free cortisol was measured using EIA kits (DetectX, Arbor Assays, Ann Arbor, MI, USA). ATR-101 was administered in 0.5% CMC-saline by oral gavage. Guinea pigs (Dunkin-Hartley, 500-600 g) and rats (SD 2-3 and 24 months) were administered ATR-101 and the adrenals were examined using protocols modified from previous studies (Dominick et al. 1993a ). Autofluorescence was visualized in freshly mounted cryosections and adjacent sections were stained with Sudan Black B or H&E.
All animal experiments and care followed policies established by the University of Michigan Committee for the Use and Care of Animals.
Cell and tissue imaging and analysis of cell viability
To measure cell proliferation in xenografts, mice were injected i.p. with 2 mg BrdU and killed 6 h after injection. BrdU incorporation was detected by immunostaining. Apoptotic cells in the xenografts were detected using the Cell Death Detection Kit (TUNEL staining, Roche). Apoptosis of cultured cells was detected using the Annexin V Apoptosis Detection Kit I (Becton Dickinson). Cytochrome c release from mitochondria was analyzed by separating mitochondria from cytosol by differential centrifugation and immunoblotting analysis. Caspase 3/7 activities were measured using the Caspase-GloW 3/7 Kit (Promega).
Cellular reducing activities were measured using MTS (Promega) and PrestoBlue (Molecular Probes) reagents. ATP levels were measured using the CellTiter-Glo Assay Kit (Promega). Cell membrane permeability was measured by incubating the cells with 50 nM SYTOX green (Invitrogen). Cells and tissue sections were incubated with the labeling reagents indicated or immunostained with the indicated antibodies after fixation using protocols modified from previous studies (Cheng et al. 2009 ). Cells and cell extracts were analyzed using indicators of cell viability and protocols modified from previous studies (Marroquin et al. 2007) . Fluorescence was visualized by microscopy, and fluorescence or luminescence intensities or absorbance was measured using a microwell plate reader.
Analysis of oxidative phosphorylation and reactive oxygen in cells and mitochondrial fractions
Mitochondrial morphology, membrane potential, and the levels of reactive oxygen species in cells were analyzed using protocols modified from previous studies (Frezza et al. 2007a) . Mitochondrial membrane potential was measured by incubating the cells with 250 nM JC-1 or 100 nM TMRM for 30 min. Mitochondrial morphology was analyzed by preloading cells with 250 nM MitoTracker Red for 2 h followed by fixation and immunostaining using anti-cytochrome c antibody. The levels of reactive oxygen species were measured by incubation with 2.5 μM DCFH, 2.5 μM MitoSOX Red, or 2.5 μM DHE for 60 min.
Rat liver mitochondrial fractions were prepared and the activities of complexes required for oxidative phosphorylation were measured as described previously (Frezza et al. 2007b) . ATP synthesis was measured using a coupled luciferase assay. Complex I activity was determined by measuring NADH absorbance. Complex III and complex IV activities were determined by measuring cytochrome c absorbance. F1F0-ATPase activity was determined by measuring phosphate release using the ATPase Assay Kit (Novus Biologicals, Littleton, CO, USA).
Detailed protocols and the sources of reagents for all experimental procedures are provided in the Supplementary Materials and methods (Supplementary Materials and methods, see section on supplementary data given at the end of this article).
Results
Effects of ATR-101 on ACC xenograft establishment and growth
We examined the effect of ATR-101 on the growth of xenografts formed by human adrenocortical carcinoma H295R cells. Mice with H295R cell xenografts of equivalent sizes were randomized into ATR-101 and vehicle cohorts. ATR-101 administration (1 mg/g/day p.o.) was started when the mean size of the xenografts reached 100 mm 3 . The growth of the xenografts was slower in the mice that were administered ATR-101 than in those that were administered vehicle (Fig. 1A) . The weight of the xenografts excised from mice that were administered ATR-101 was lower than that of xenografts excised from control mice. ATR-101 administration had no significant effect on the mean body weight of the mice and did not cause overt symptoms of weakness or fatigue (Fig. 1A , data not shown).
We determined the effect of ATR-101 on xenograft establishment by starting ATR-101 (0.7 mg/g/day p.o.) or vehicle administration 2 weeks after cell implantation. This protocol is designed to mimic the use of adjuvant chemotherapy in conjunction with surgery to counteract ACC tumor recurrence (Lindhe & Skogseid 2010) . The mice were randomized into ATR-101 and control cohorts that had similar distributions of the sizes of the swellings produced by cell injection, which was taken to indicate that comparable numbers of H295R cells were implanted into the mice. The proportion of the mice that developed xenografts and the rates of xenograft growth were lower for mice that were administered ATR-101 than for the control mice ( Fig. 1B and Table 1 ). The cortisol levels of mice that were administered ATR-101 were lower on average than those of control mice with H295R cell implants (Fig. 1B) . However, the cortisol levels of individual mice varied over a wide range. No new xenografts were observed when ATR-101 administration was discontinued after 88 days, suggesting that ATR-101 administration eradicated the implanted cells in most mice. Re-implantation of H295R cells into the contra lateral flank in the absence of ATR-101 administration produced xenografts in all of the mice.
To determine the minimum serum concentration of ATR-101 that affected xenograft growth in mice, we evaluated the effects of different doses of ATR-101. An ATR-101 dose of 0.3 mg/g/day p.o. had a transient effect on xenograft growth in a subset of the mice (data not shown). At this dose, the serum ATR-101 concentration reached a maximum of 40 μM at 60 -150 min after initial administration, and then decreased with a t ½ of about 6 h (Fig. 1C) .
Cells that were re-isolated from the few xenografts that formed in mice during ATR-101 administration had the same susceptibility to ATR-101 as the cells that were implanted into the mice (Fig. 1D) . ATR-101 administration therefore did not give rise to ATR-101 resistance in the xenografts of these mice.
We examined cell proliferation and apoptosis in the cortex of the xenografts to determine how ATR-101 suppressed xenograft growth. ATR-101 administration did not alter the proportions of cells that incorporated BrdU or those that reacted with anti-Ki67 antibodies (Fig. 1E) . In contrast, the proportion of cells that produced TUNEL signal was higher in the xenografts from mice that were administered ATR-101 than in xenografts from control mice. ATR-101 administration therefore increased the proportion of apoptotic cells in mouse xenografts.
Effects of ATR-101 and related compounds on cultured ACC-derived cells
We compared the effects of culturing the ACC-derived H295R cell line with different concentrations of ATR-101 on several independent characteristics that are used as indicators of cell viability. ATR-101 caused rapid and opposite changes in the rates of formazan (MTS) vs resorufin (Prestoblue) reduction in H295R cells ( Fig. 2A) . The balance of cellular-reducing compounds shifted within tens of minutes after ATR-101 addition to cultured cells. The same ATR-101 concentrations that shifted the balance of reducing compounds depleted the ATP in H295R cells (Fig. 2B) . The ATP level was reduced within 2 h after ATR-101 addition and was depleted within 12 h (see below). After 16 h of culture with ATR-101, the cell membrane became permeable to SYTOX (Fig. 2C) . When the cells were washed 4 h after ATR-101 addition, a majority of the cells recovered and resumed growth (Fig. 2D) . The cells did not recover when ATR-101 was removed after 20 h.
We compared the cytotoxicity of ATR-101 with that of another ACAT inhibitor (Sandoz 58-035) as well as a compound that is structurally related to ATR-101 (S484709). No ATP depletion or membrane permeabilization was observed in H295R cells that were cultured with either of these compounds (Fig. 2E) . Moreover, the concentration of ATR-101 that was required for cytotoxicity was about three orders of magnitude higher than the concentration that inhibits ACAT activity in vitro (Trivedi et al. 1994) . Similarly, the doses of ATR-101 that were required to suppress xenograft establishment and growth in mice were more than an order of magnitude larger than those that are required to reduce plasma cholesterol levels in rats, rabbits, guinea pigs, and dogs (Krause et al. 1993) . The cytotoxicity and the suppression of xenograft formation by ATR-101 are therefore likely to require activities unrelated to ACAT inhibition.
We investigated whether ATR-101 caused the apoptosis of cultured H295R cells. Annexin V labeled a majority of the cells that were cultured with ATR-101, and all of the cells that were labeled by propidium iodide (Fig. 2F) . Cytochrome c was released into the cytoplasm and the caspase-3/7 activity increased in cells cultured with ATR-101 (Fig. 2G) . Culture of cells with minocycline (Zhu et al. 2002) suppressed cytochrome c release, caspase-3/7 activation, and ATP depletion by ATR-101. ATR-101 therefore caused H295R cell apoptosis both in culture and in xenografts.
Effects of ATR-101 on mitochondrial membrane potential and on mitochondrial morphology
To investigate the causes for the rapid depletion of ATP in the presence of ATR-101, we examined the mitochondria of H295R cells that were cultured with ATR-101. ATR-101 caused an increase in the mitochondrial membrane potential as detected by JC-1 as well as by TMRM fluorescence (Fig. 3A) . This increase occurred within hours of the addition of ATR-101 to cultured cells (Fig. 3B) . Thus, ATR-101 had simultaneous and opposite effects on the mitochondrial membrane potential and on the ATP level shortly after addition (Fig. 4C) . After 3 h, the mitochondrial membrane potential gradually declined and reached a level below that of untreated cells 16 h after ATR-101 addition at the same time as the cellular energy charge was depleted.
We compared the morphologies of mitochondria in cells that were cultured with vehicle and with ATR-101. Mitochondria that were visualized by MitoTracker fluorescence and anti-cytochrome c immunofluorescence appeared as small round puncta in cells cultured with ATR-101, whereas mitochondria in cells cultured with vehicle appeared as long reticular strands (Fig. 3C) . ATR-101 therefore caused mitochondrial fragmentation in parallel with its effects on mitochondrial membrane potential and ATP depletion.
Effects of ATR-101 on reactive oxygen levels
We tested the hypothesis that the increase in mitochondrial membrane potential caused the release of reactive oxygen from the electron transport chain. Cells that were cultured with ATR-101 had elevated levels of reactive oxygen species detected by 2ʹ,7ʹ-dichloro-dihydrofluorescein diacetate (DCFH), dihydroethidium (DHE), 
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and MitoSOX (hydroxyethidine) fluorescence (Fig. 4A) . DCFH can be oxidized by many different reactive oxygen species, whereas DHE and MitoSOX react primarily with superoxide (Robinson et al. 2006 , Dikalov et al. 2007 . MitoSOX is enriched in mitochondria and binds nucleic acids upon oxidation, resulting in nuclear fluorescence. The DCFH fluorescence increased in parallel with the mitochondrial membrane potential, whereas the MitoSOX fluorescence increased only after ATP depletion ( Fig. 4B and C) .
Effects of lipophilic antioxidants on ATR-101 cytotoxicity
We tested whether the release of reactive oxygen mediated ATR-101 cytotoxicity by determining if antioxidants protected the cells from the effects of ATR-101. Addition 
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of α-tocopherol (vitamin E) to the cells in combination with ATR-101 suppressed the increase in superoxide levels, caspase-3/7 activation, and membrane permeabilization ( Fig. 5A and B) . By contrast, ATR-101 had the same effect on JC-1 fluorescence when added together with α-tocopherol, indicating that α-tocopherol did not block ATR-101 entry into cells or its effect on the mitochondrial membrane potential ( Fig. 5A and B ). Higher α-tocopherol concentrations suppressed the effects of proportionately higher ATR-101 concentrations on the ATP levels of cells (Fig. 5C ). The counterbalancing effects of ATR-101 and α-tocopherol on the ATP level suggest that they had directly opposing effects on processes that were critical for the maintenance of cellular ATP. Several different tocopherols suppressed ATP depletion by ATR-101 (Fig. 5D ). These tocopherols also have antioxidant activity. In contrast, α-tocopherol succinate did not prevent ATP depletion by ATR-101. α-tocopherol succinate does not have antioxidant activity, but retains many functions of α-tocopherol that are independent of its antioxidant activity (Neuzil et al. 2001 , Birringer et al. 2003 , Galli et al. 2004 . Tocopherol protection from ATR-101 cytotoxicity therefore correlated with antioxidant activity.
Structurally unrelated lipophilic antioxidants, including 3-phytylmenadione (vitamin K) and probucol, also protected cells from the release of reactive oxygen and ATP depletion in the presence of ATR-101 ( Fig. 6A and  B) . None of these antioxidants prevented the change in JC-1 fluorescence caused by ATR-101, indicating that mitochondrial membrane hyperpolarization preceded the release of reactive oxygen and its cytotoxic effects (Fig. 6C) . Nevertheless, lipophilic antioxidants restored the ATP level in cells cultured with ATR-101, suggesting that the elevation of reactive oxygen levels contributed to ATP depletion. None of the many hydrophilic antioxidants tested prevented ATP depletion by ATR-101, indicating that protection from ATR-101 cytotoxicity required antioxidant activity in a lipophilic environment (Fig. 6D) .
Effects of glycolysis on ATR-101 cytotoxicity
H295R cells that were cultured with glycolytic substrates maintained their ATP levels and cell membrane integrity in the presence of ATR-101 (Fig. 7A) . Conversely, culture of H295R cells with 2-deoxy-d-glucose aggravated the ATP depletion and membrane permeabilization caused by ATR-101 (Fig. 7B) . ATR-101 cytotoxicity therefore correlated with a reliance on respiration for ATP synthesis. Glycolytic substrates did not eliminate the rapid increase in mitochondrial membrane potential and DCFH reactive oxygen caused by ATR-101 but they suppressed the slow increase in MitoSOX fluorescence ( Fig. 7C and D) . The
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increases in mitochondrial membrane potential and reactive oxygen levels over the short term were therefore not sufficient for ATR-101 cytotoxicity: additional factors over the long term, potentially including ATP depletion or elevated superoxide levels, were therefore required for ATR-101 cytotoxicity.
Relationships between ATR-101 cytotoxicity and oxidative phosphorylation
To identify the steps in oxidative phosphorylation that were affected by ATR-101 in cells, we measured the combined effects of ATR-101 and inhibitors of individual steps of oxidative phosphorylation on the ATP level and on cell membrane permeability. ATR-101 and inhibitors of complex I (rotenone) and of complex III (antimycin A) had synergistic effects on the ATP level and on SYTOX fluorescence (Fig. 8A) . ATR-101 and the complex IV inhibitor sodium azide as well as the uncoupler CCCP had additive effects on the ATP level and moderately synergistic effects on SYTOX fluorescence. By contrast, ATR-101 and the F1F0-ATP synthase inhibitor oligomycin had additive effects both on the ATP level and on the SYTOX fluorescence. Thus, ATR-101 had synergistic effects in combination with compounds that inhibit the early steps of the electron transport pathway, additive effects in combination with compounds that inhibit ATP synthase, and different effects on the ATP level and on cell membrane permeability in combination with compounds that inhibit the late steps of the electron transport pathway or compounds that dissipate the proton motive force. We determined the combined effects of ATR-101 with CCCP, oligomycin, as well as DCCD on the mitochondrial membrane potential. CCCP reversed the increase in the JC-1 fluorescence ratio caused by ATR-101 alone (Fig. 8B) . In contrast, both oligomycin and DCCD further increased the JC-1 fluorescence ratio in combination with ATR-101. Taken together, these results are consistent with the interpretation that ATR-101 blocks ATP synthase activity and does not inhibit electron transport directly.
Effects of ATR-101 on membrane potential and on oxidative phosphorylation in mitochondrial fractions
To establish whether ATR-101 had direct effects on mitochondria, we investigated the effects of ATR-101 on mitochondrial fractions that were prepared by differential centrifugation (Fig. 9A) . Mitochondria that respired in the presence of ATR-101 produced higher JC-1 fluorescence than mitochondria that respired in the absence of ATR-101 (Fig. 9B) . ATR-101 therefore had a direct effect on the membrane potential generated by mitochondrial respiration. The increase in JC-1 fluorescence required an electron donor and was prevented by CCCP.
ATR-101 reduced the amount of ATP that was produced by respiring mitochondria (Fig. 9C) . ATR-101 inhibited ATP synthesis when glutamate and malate, which are utilized by complex I, or succinate, which is utilized by complex II, were used as electron donors (Fig. 9D) . Similar ATR-101 concentrations increased the mitochondrial membrane potential and inhibited ATP synthesis in mitochondrial fractions as well as in cultured cells.
We examined the effects of ATR-101 on the individual steps of oxidative phosphorylation. ATR-101 had no detectable effect on uncoupled NADH oxidation by complex I, on cytochrome c reduction by complex III, or on cytochrome c oxidation by complex IV (Fig. 9D and E) . In contrast, ATR-101 inhibited F1F0-ATPase activity in mitochondrial fractions (Fig. 9F) . Similar ATR-101 concentrations reduced F1F0-ATPase activity, increased JC-1 fluorescence, and reduced ATP synthesis. These results indicate that ATR-101 increased the mitochondrial membrane potential and inhibited oxidative phosphorylation by direct inhibition of F1F0-ATPase.
Role of reactive oxygen in ATR-101 adrenalytic activity in vivo
We investigated the significance of the molecular mechanisms of ATR-101 action identified in vitro by studying the adrenalytic effect of ATR-101 in guinea pigs. The adrenal cortex of guinea pigs that were administered ATR-101 for two weeks contained a layer of autofluorescent foci (Fig. 10A) . The fluorescence intensities of these foci were up to five-fold higher than the fluorescence of other layers of the adrenal cortex and of the corresponding layer of the adrenal cortex from control animals. The autofluorescent layer contained brown granules and the autofluorescence quenched by Sudan Black (Fig. 10B and C).
Tissue autofluorescence with pigmented granules that is quenched by Sudan Black is characteristic of oxidized lipids known as lipofuscin. The spectrum of the autofluorescent foci in the adrenals from guinea pigs that were administered ATR-101 was characteristic of lipofuscins ( Fig. 10E) (Georgakopoulou et al. 2013) . No autofluorescence or granules were observed in the adrenal cortex from guinea pigs that were killed 6 -8 h after the administration of single dose (500 mg/kg p.o.) of ATR-101, suggesting that lipofuscin accumulation required an 
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extended period of ATR-101 exposure. The layer of autofluorescent foci overlapped with the region of the zona fasciculata that exhibited adrenalytic damage in guinea pigs that were administered ATR-101 (Fig. 10D) . The overlap between these regions implicates reactive oxygen species as a cause of the adrenalytic activity of ATR-101. ATR-101 administration had no detectable effect on the low level of autofluorescence or on the integrity of the adrenal cortex in young rats (data not shown). ATR-101 also had no detectable effect on the autofluorescence of the adrenal cortex of old rats, which had scattered autofluorescent cells in the zona reticularis. Changes in the morphology of the adrenal cortex were observed in some of the old rats that were administered ATR-101. These changes were not as extensive or reproducible as those that were observed in guinea pigs. Also, although adrenalytic effects of ATR-101 in guinea pigs were observed consistently at a dose of 0.1 g/kg/day p.o., as reported previously (Dominick et al. 1993a) , the variable effects of ATR-101 on the adrenal cortex of rats were observed at a dose of 1 g/kg/day p.o. The difference between the effects of ATR-101 on lipofuscin accumulation in the adrenal cortex of guinea pigs vs rats correlated with the difference between the adrenalytic effects of ATR-101 in these species (Reindel et al. 1994 ).
Discussion
The genetic and epigenetic causes of adrenocortical carcinoma are complex (Fonseca et al. 2012 , Assie et al. 2014 , Juhlin et al. 2015 , Pinto et al. 2015 . Clinical trials of molecularly targeted agents have not demonstrated therapeutic benefit for a majority of patients (O'Sullivan et al. 2014 , Fassnacht et al. 2015 , Quinkler et al. 2008 , Saif et al. 2012 .
ATR-101 counteracted the establishment and growth of xenografts by ACC-derived H295R cells in CB17-SCID mice; however, it did not shrink established xenografts. The lower efficacy of ATR-101 against established xenografts could be due to changes in ATR-101 access to, or the metabolism of, H295R cells at different stages of xenograft formation. Compounds with a higher efficacy and potency against established xenografts could have better prospects of therapeutic benefit.
Multiple independent lines of evidence implicate the inhibition of oxidative phosphorylation in the molecular mechanism for ATR-101 cytotoxicity. ATR-101 inhibited F1F0-ATP synthase and ATP synthesis in isolated mitochondria and elevated the mitochondrial membrane potential and depleted ATP concurrently in cells. This mitochondrial dysfunction caused the release of reactive oxygen and triggered cytochrome c release, resulting in caspase-mediated apoptosis. The cytotoxicity of ATR-101 was suppressed by antioxidants as well as by glycolytic precursors. Both ATP depletion and the release of reactive oxygen species are likely to contribute to ATR-101 cytotoxicity (Fig. 9G) .
Similar ATR-101 concentrations were required for the inhibition of oxidative phosphorylation in isolated mitochondria and for the elevation of mitochondrial membrane potential and release of reactive oxygen in cells. The concentration of ATR-101 in serum that was required for xenograft suppression in mice was similar to the concentration of ATR-101 that inhibited mitochondrial functions in cells and in vitro. The effects of ATR-101 on mitochondrial fragmentation and their functions in cultured cells corresponded with its effects on mitochondrial morphology and the ATP levels in the adrenal cortex (Dominick et al. 1993a) . ATR-101 increased the reactive oxygen levels in both cultured cells and in the zona fasciculata. It is likely that the same mechanisms mediated these effects of ATR-101 in cultured cells and in vivo.
Many inhibitors of electron transport as well as of F1F0-ATPase cause cell death under conditions that require respiration, but not under glycolytic conditions (Marroquin et al. 2007 , Tettamanti et al. 2008 , Poli et al. 2013 . Numerous inhibitors of oxidative phosphorylation have been investigated as potential anti-cancer agents (Rohlena et al. 2013) . A majority of these agents have adverse effects that are likely to be due to mitochondrial dysfunctions in normal tissues. The inhibition of mitochondrial functions and the release of reactive oxygen have many effects on carcinogenesis and could have both beneficial and adverse consequences for ACC patients (Ralph et al. 2010 , Kuznetsov et al. 2011 .
Many compounds that are in clinical use or in trials for the treatment of ACC cause mitochondrial dysfunctions in cancer cell lines (Andre et al. 2002 , Bull et al. 2012 , Hescot et al. 2013 , Marullo et al. 2013 . The mitochondria of the adrenal cortex have unique functions, including corticosteroid biosynthesis, making it plausible that the inhibition of mitochondrial functions can selectively kill cells of adrenocortical origin. Based on the selective oxidative damage caused by ATR-101 in the adrenal cortex of guinea pigs and its apoptotic effects on ACC-derived cells in culture and in xenografts, we speculate that this compound can disrupt mitochondrial functions in tumors of adrenocortical origin.
The close correspondence between the layer of the adrenal cortex that accumulates autofluorescent lipofuscin and that which is subject to adrenalytic damage in guinea pigs that are administered ATR-101 suggests that the 23:4 adrenalytic activity of ATR-101 involves lipid oxidation. The ATR-101-dependent accumulation of lipofuscin in the guinea pig adrenal cortex, but not in the rat adrenal cortex, is consistent with the species-specific differences in the adrenalytic activity of ATR-101 (Reindel et al. 1994) . The mechanisms that cause the species-specific differences in the adrenalytic activity of ATR-101 remain unknown.
The difference in lipofuscin accumulation and adrenalytic damage between guinea pigs and rats that were administered ATR-101 correlates with the difference in the α-tocopherol concentrations of rat and guinea pig adrenals (Burczynski et al. 1999) . Mice that are fed a tocopherol-deficient diet have higher lipofuscin levels in the adrenal cortex, but not in the brain (Davies et al. 1987) . Microsomes from the outer zone of the adrenal cortex of guinea pigs that are fed a tocopherol-deficient diet have higher levels of lipid peroxidation (Staats et al. 1988) . Chemical depletion of tocopherols from microsomes isolated from the human adrenal cortex also increases lipid peroxidation (Takayanagi et al. 1986) . It is therefore likely that lipid oxidation in the adrenal cortex is a general consequence of conditions that increase the level of reactive oxygen in this tissue.
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